Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Related to this article
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.
Advertisement
Advertisement
Trending on OncLive
1
FDA Flashback: Breast Cancer Decisions and News From June 2026
2
Zanubrutinib Extends TTNT, OS vs Acalabrutinib in Real-World R/R MCL
3
FDA Approval Insights: Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma: With Alex Herrera, MD
4
FDA Approves Pegfilgrastim Biosimilar for Non-Myeloid Malignancies
5